The effects of bolus administration of opioids on cerebrospinal fluid pressure in patients with supratentorial lesions.
In many studies reporting an increase in cerebrospinal fluid pressure (CSFP) after opioid administration, concomitant decreases in mean arterial pressure (MAP) have been observed. Autoregulatory cerebral vasodilation may therefore have been a factor in the CSFP increases. We tested the hypothesis that increases in CSFP after bolus injection of opioids could be minimized by modifying concomitant decreases in MAP with phenylephrine. Thirty-three patients with supratentorial mass lesions were studied in a randomized, prospective, double-blind, saline-controlled comparative trial. The principal outcome measures were lumbar CSFP, MAP, and heart rate (HR). Study drugs, sufentanil 0.8 micrograms/kg (n = 12), fentanyl 4.5 micrograms/kg (n = 11), or normal saline (n = 10), were injected intravenously (IV) during stable general anesthesia with 0.3-0.7 minimum alveolar anesthetic concentration (MAC) of isoflurane in oxygen and controlled ventilation (end-tidal carbon dioxide 32-35 mm Hg). Phenylephrine 50-100 micrograms was injected IV when MAP decreased by more than 15% of initial values, and atropine 0.5 mg IV when HR decreased to less than 45 bpm. Opioid administration was associated with significant decreases in MAP, 21 +/- 9 mm Hg (mean +/- SD) in the sufentanil group and 16 +/- 7 mm Hg in the fentanyl group; P < 0.001. These decreases in MAP were of short duration (i.e., corrected with 1-2 min). Patients in the sufentanil group needed more phenylephrine than patients in the fentanyl group (170 +/- 89 micrograms vs 100 +/- 47 micrograms; P < 0.05). No significant change in the CSFP was seen in either the sufentanil (1 +/- 6 mm Hg) or fentanyl-treated patients (O +/- 2 mm Hg). No significant changes in MAP or CSFP were observed in the saline-treated patients. HR decreased after injection of either study drug (P < 0.01) but remained unchanged in the saline group. In summary, during stable anesthesia with isoflurane in oxygen, bolus injections of fentanyl or sufentanil, despite producing rapidly corrected mean decreases in MAP of 18% and 25%, respectively, were not associated with any change in CSFP.
Jamali
S
S
Departement of Anesthesiology and Surgical Intensive Care, Bicêtre Hospital, France.
Ravussin
P
P
Archer
D
D
Goutallier
D
D
Parker
F
F
Ecoffey
C
C
D000328:Adult; D000368:Aged; D018685:Anesthetics, Inhalation / Q000008:administration & dosage; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage; D001285:Atropine / Q000008:administration & dosage; D001794:Blood Pressure / Q000187:drug effects; D001919:Bradycardia / Q000517:prevention & control; D002536:Cerebral Arteries / Q000187:drug effects; D015170:Cerebrospinal Fluid Pressure / Q000187:drug effects*; D004311:Double-Blind Method; D005283:Fentanyl / Q000494:pharmacology*; D006339:Heart Rate / Q000187:drug effects; D006706:Homeostasis / Q000187:drug effects; D006801:Humans; D007022:Hypotension / Q000517:prevention & control; D007275:Injections, Intravenous; D007530:Isoflurane / Q000008:administration & dosage; D008875:Middle Aged; D010656:Phenylephrine / Q000008:administration & dosage; D010919:Placebos; D011446:Prospective Studies; D012121:Respiration, Artificial; D017409:Sufentanil / Q000494:pharmacology*; D015173:Supratentorial Neoplasms / Q000601:surgery*; D016896:Treatment Outcome; D014662:Vasoconstrictor Agents / Q000008:administration & dosage; D014664:Vasodilation
D018685:Anesthetics, Inhalation; D000889:Anti-Arrhythmia Agents; D010919:Placebos; D014662:Vasoconstrictor Agents; D010656:Phenylephrine; D001285:Atropine; D017409:Sufentanil; D007530:Isoflurane; D005283:Fentanyl